Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Entrectinib

FDA-approved product (capsule, oral), marketed as Rozlytrek.

Registered studies
46
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Entrectinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Neoplasm
  • Non-small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other protein kinase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli50.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae39.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

46registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Entrectinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-10.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-11.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-10.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Entrectinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs

    NCT05159245 · start 2021-12-10

    Registered record
    Registry ID
    NCT05159245
    Conditions
    Advanced Cancer; Solid Tumor; Haematological Malignancy
    Interventions
    Alectinib; Cobimetinib; Vismodegib; Trastuzumab+Pertuzumab; Entrectinib; Atezolizumab; Vemurafenib; Regorafenib; Apalutamide; Abemaciclib; Tepotinib; Dabrafenib; Trametinib; Dabrafenib+Trametinib; Pemigatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2021-12-10
    Completion
    2026-11-25
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Cancer; Solid Tumor; Haematological Malignancy
    InterventionAlectinib; Cobimetinib; Vismodegib; Trastuzumab+Pertuzumab +11 more
    PhasePhase 2
    Registry statusRecruiting

  • A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases

    NCT04603807 · start 2021-09-30

    Registered record
    Registry ID
    NCT04603807
    Conditions
    Carcinoma, Non-Small-Cell Lung
    Interventions
    Entrectinib; Crizotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2021-09-30
    Completion
    2028-01-29
    Enrolment
    217

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Non-Small-Cell Lung
    InterventionEntrectinib; Crizotinib
    PhasePhase 3
    Registry statusActive not recruiting

  • Preoperative ROS1-TKI Therapy for ROS1 Fusion-Positive Locally Advanced Lung Adenocarcinoma

    NCT07700836 · start 2021-07-01

    Registered record
    Registry ID
    NCT07700836
    Conditions
    ROS1 Fusion-Positive Lung Adenocarcinoma
    Interventions
    ROS1-TKI Therapy
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-07-01
    Completion
    2025-11-17
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionROS1 Fusion-Positive Lung Adenocarcinoma
    InterventionROS1-TKI Therapy
    PhaseNot recorded
    Registry statusCompleted

  • Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

    NCT06482086 · start 2021-06-01

    Registered record
    Registry ID
    NCT06482086
    Conditions
    Locally Advanced Thyroid Gland Carcinoma
    Interventions
    Anlotinib; Lenvatinib; Sorafenib; Donafenib; Everolimus; Apatinib; Dabrafenib + Trametinib; Cabozantinib; Vandetanib; Entrectinib; Pralsetinib; Larotrectinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2021-06-01
    Completion
    2025-12-01
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLocally Advanced Thyroid Gland Carcinoma
    InterventionAnlotinib; Lenvatinib; Sorafenib; Donafenib +8 more
    PhasePhase 2
    Registry statusRecruiting

  • A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors

    NCT04644315 · start 2021-05-24

    Registered record
    Registry ID
    NCT04644315
    Conditions
    Neoplasms; Colorectal Neoplasms; Melanoma; Pancreatic Neoplasms; Sarcoma; Ovarian Neoplasms; Brain Neoplasms; Thyroid Neoplasms; Neuroendocrine Tumors; Cholangiocarcinoma; Salivary Gland Neoplasms; Head and Neck Neoplasms; Thyroid Cancer, Papillary; Lymphoma, Large-Cell, Anaplastic; Neoplasms by Site; Respiratory Tract Neoplasms; Thoracic Neoplasms; Respiratory Tract Diseases; Carcinoma, Bronchogenic; Bronchial Neoplasms; Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Central Nervous System
    Interventions
    Alectinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2021-05-24
    Completion
    2022-05-16
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeoplasms; Colorectal Neoplasms; Melanoma; Pancreatic Neoplasms +24 more
    InterventionAlectinib
    PhasePhase 2
    Registry statusTerminated

  • Improving Public Cancer Care by Implementing Precision Medicine in Norway

    NCT04817956 · start 2021-04-01

    Registered record
    Registry ID
    NCT04817956
    Conditions
    Cancer Metastatic
    Interventions
    Atezolizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2021-04-01
    Completion
    2045-04-30
    Enrolment
    3,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer Metastatic
    InterventionAtezolizumab
    PhasePhase 2
    Registry statusRecruiting

  • Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

    NCT04589845 · start 2021-01-18

    Registered record
    Registry ID
    NCT04589845
    Conditions
    Solid Tumors
    Interventions
    Entrectinib; Entrectinib; Alectinib; Atezolizumab; Ipatasertib; Trastuzumab emtansine; Inavolisib; Belvarafenib; Pralsetinib; Divarasib; Camonsertib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2021-01-18
    Completion
    2032-09-25
    Enrolment
    920

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumors
    InterventionEntrectinib; Entrectinib; Alectinib; Atezolizumab +7 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)

    NCT04551495 · start 2021-01-14

    Registered record
    Registry ID
    NCT04551495
    Conditions
    Invasive Lobular Breast Carcinoma; ER+ Breast Cancer; HER2-negative Breast Cancer
    Interventions
    Entrectinib; Letrozole; Goserelin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2021-01-14
    Completion
    2025-01
    Enrolment
    65

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInvasive Lobular Breast Carcinoma; ER+ Breast Cancer; HER2-negative Breast Cancer
    InterventionEntrectinib; Letrozole; Goserelin
    PhasePhase 2
    Registry statusUnknown

  • A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

    NCT04632992 · start 2021-01-13

    Registered record
    Registry ID
    NCT04632992
    Conditions
    Advanced Unresectable or Metastatic Solid Malignancy
    Interventions
    Entrectinib; Inavolisib; Alectinib; Ipatasertib; Atezolizumab; Trastuzumab Emtansine; Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf; Tucatinib; Investigator's Choice of Chemotherapy; Paclitaxel; Tiragolumab; Pralsetinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-01-13
    Completion
    2024-02-27
    Enrolment
    252

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Unresectable or Metastatic Solid Malignancy
    InterventionEntrectinib; Inavolisib; Alectinib; Ipatasertib +8 more
    PhasePhase 2
    Registry statusCompleted

  • Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma

    NCT04589832 · start 2021-01-11

    Registered record
    Registry ID
    NCT04589832
    Conditions
    Uveal Melanoma
    Interventions
    PAC-1; Entrectinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2021-01-11
    Completion
    2022-06-24
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUveal Melanoma
    InterventionPAC-1; Entrectinib
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

    NCT04302025 · start 2020-11-06

    Registered record
    Registry ID
    NCT04302025
    Conditions
    Non-small Cell Lung Cancer
    Interventions
    Alectinib; Entrectinib; Vemurafenib; Cobimetinib; Pralsetinib; Atezolizumab; SBRT; Resection; Chemotherapy; Divarasib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2020-11-06
    Completion
    2030-05-30
    Enrolment
    99

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer
    InterventionAlectinib; Entrectinib; Vemurafenib; Cobimetinib +6 more
    PhasePhase 2
    Registry statusRecruiting

  • The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

    NCT04591431 · start 2020-10-07

    Registered record
    Registry ID
    NCT04591431
    Conditions
    Breast Cancer; Gastrointestinal Cancer; Non Small Cell Lung Cancer; Other Cancer
    Interventions
    Erlotinib; Trastuzumab; Trastuzumab emtansine; Pertuzumab; Lapatinib; Everolimus; Vemurafenib; Cobimetinib; Alectinib; Brigatinib; Palbociclib; Ponatinib; Vismogedib; Itacitinib; Ipatasertib; Entrectinib; Atezolizumab; Nivolumab; Ipilimumab; Pemigatinib; Oncology Drugs; Pralsetinib; Selpercatinib; Talazoparib; Tepotinib; Alpelisib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2020-10-07
    Completion
    2025-06
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Gastrointestinal Cancer; Non Small Cell Lung Cancer; Other Cancer
    InterventionErlotinib; Trastuzumab; Trastuzumab emtansine; Pertuzumab +22 more
    PhasePhase 2
    Registry statusUnknown

  • Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

    NCT04322890 · start 2020-04-16

    Registered record
    Registry ID
    NCT04322890
    Conditions
    Non Small Cell Lung Cancer; EGFR Gene Mutation; ALK Gene Mutation; ROS1 Gene Mutation; MET Gene Mutation
    Interventions
    Osimertinib; Alectinib 150 MG; Crizotinib 250 MG; Savolitinib, Crizotinib.; Chemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2020-04-16
    Completion
    2027-12-24
    Enrolment
    6,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon Small Cell Lung Cancer; EGFR Gene Mutation; ALK Gene Mutation; ROS1 Gene Mutation +1 more
    InterventionOsimertinib; Alectinib 150 MG; Crizotinib 250 MG; Savolitinib, Crizotinib. +1 more
    PhasePhase 2
    Registry statusRecruiting

  • Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

    NCT03878524 · start 2020-04-01

    Registered record
    Registry ID
    NCT03878524
    Conditions
    Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Anatomic Stage IV Breast Cancer AJCC v8; Anemia; Ann Arbor Stage III Hodgkin Lymphoma; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Castration-Resistant Prostate Carcinoma; Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Hematopoietic and Lymphoid System Neoplasm; Locally Advanced Pancreatic Adenocarcinoma; Metastatic Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Pancreatic Adenocarcinoma; Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Primary Myelofibrosis; Recurrent Acute Lymphoblastic Leukemia; Recurrent Acute Myeloid Leukemia; Recurrent Chronic Lymphocytic Leukemia; Recurrent Chronic Myelogenous
    Interventions
    Abemaciclib; Abiraterone; Afatinib; Bevacizumab; Bicalutamide; Biospecimen Collection; Bortezomib; Cabazitaxel; Cabozantinib; Capecitabine; Carboplatin; Celecoxib; Cobimetinib; Copanlisib; Dabrafenib; Dacomitinib; Darolutamide; Dasatinib; Doxorubicin; Durvalumab; Enasidenib; Entrectinib; Enzalutamide; Erlotinib; Everolimus; Fluorouracil; Idelalisib; Imatinib; Ipilimumab; Lenvatinib; Leucovorin; Lorlatinib; Losartan; Nab-paclitaxel; Neratinib; Nivolumab; Olaparib; Oxaliplatin; Palbociclib; Panobinostat; Pembrolizumab; Pertuzumab; Ponatinib; Quality-of-Life Assessment; Regorafenib; Ruxolitinib; Sirolimus; Sorafenib; Sunitinib; Trametinib; Trastuzumab Emtansine; Tretinoin; Vemurafenib; Venetoclax; Vismodegib; Vorinostat
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2020-04-01
    Completion
    2020-12-10
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Anatomic Stage IV Breast Cancer AJCC v8; Anemia; Ann Arbor Stage III Hodgkin Lymphoma +19 more
    InterventionAbemaciclib; Abiraterone; Afatinib; Bevacizumab +52 more
    PhasePhase 1
    Registry statusTerminated

  • A Study to Investigate the Effect of Impaired Hepatic Function on the Pharmacokinetics of Entrectinib in Volunteers With Different Levels of Hepatic Function

    NCT04226833 · start 2020-02-11

    Registered record
    Registry ID
    NCT04226833
    Conditions
    Hepatic Insufficiency
    Interventions
    entrectinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-02-11
    Completion
    2021-09-27
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatic Insufficiency
    Interventionentrectinib
    PhasePhase 1
    Registry statusCompleted